Reducing gastric secretions—a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?

Feuer DJ, Broadley KE, Shepherd JH, Barton DP (2000) Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev (4):CD002764

Pameijer CR, Mahvi DM, Stewart JA, Weber SM (2005) Bowel obstruction in patients with metastatic cancer: does intervention influence outcome? Int J Gastrointest Cancer 35(2):127–133. doi: 10.1385/IJGC:35:2:127

Ripamonti C, Bruera E (2002) Palliative management of malignant bowel obstruction. Int J Gynecol Cancer 12(2):135–143. doi: 10.1046/j.1525-1438.2002.01103.x

Australian Therapeutic Guidelines Palliative Care 2nd ed. Melbourne, Australia: Therapeutic Guidelines Limited; 2005

Ouellette J, Patterson L, P. T. Fast Fact and Concept #091: Interventional Options for Malignant Upper GI Obstruction. American Academy of Hospice and Palliative Care, ( www.epercmcw.edu ), 2007.

Clark K, Lam L, Gibson S, Currow D (2009) The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia (in press).

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12. doi: 10.1016/0197-2456(95) 00134-4

Begg CB (1994) Publication Bias. Russell Sage Foundation, New York City

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

Australian Therapeutic Guidelines Gastrointestinal 1st ed. Melbourne, Australia: Therapeutic Guidelines Limited; 2008

Krouse RS (2007) The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research. J Pain Symptom Manage 34(1 Suppl):S1–S6. doi: 10.1016/j.jpainsymman.2007.04.005

Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J et al (2007) Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage 34(1 Suppl):S49–S59. doi: 10.1016/j.jpainsymman.2007.04.011

Ripamonti CI, Easson AM, Gerdes H (2008) Management of malignant bowel obstruction. Eur J Cancer 44(8):1105–1115. doi: 10.1016/j.ejca.2008.02.028

Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F et al (2001) Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9(4):223–233. doi: 10.1007/s005200000198

Salem MR, Wong AY, Mani M, Bennett EJ, Toyama T (1976) Premedicant drugs and gastric juice pH and volume in paediatric patients. Anesthesiology 44(3):216–219. doi: 10.1097/00000542-197603000-00010

Hatlebakk JG, Berstad A (1996) Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol 31(10):954–958. doi: 10.3109/00365529609003113

Pisegna JR (2001) Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 32(1):27–32. doi: 10.1097/00004836-200101000-00007

Miller R (1984) Pharmacokinetics and bioavailability of ranitidine in humans. J Pharm Sci 73(10):1376–1379. doi: 10.1002/jps.2600731013

Agar M, Webster R, Lacey J, Donovan B, Walker A (2004) The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients. J Pain Symptom Manage 28(6):529–531. doi: 10.1016/j.jpainsymman.2004.10.005

Davis MP, Furste A (1999) Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage 18(3):153–154. doi: 10.1016/S0885-3924(99) 00063-9

Escolano F, Castano J, Lopez R, Bisbe E, Alcon A (1992) Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery. Br J Anaesth 69(4):404–406. doi: 10.1093/bja/69.4.404

Hendolin H, Suojaranta-Ylinen R, Alhava E (1993) Effect of single-dose omeprazole and ranitidine on gastric juice acidity and volume in patients undergoing laparotomy. Acta Anaesthesiol Scand 37(5):484–487. doi: 10.1111/j.1399-6576.1993.tb03751.x

Nishina K, Mikawa K, Maekawa N, Takao Y, Shiga M, Obara H (1996) A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery. Anesth Analg 82(4):832–836. doi: 10.1097/00000539-199604000-00027

Nishina K, Mikawa K, Takao Y, Shiga M, Maekawa N, Obara H (2000) A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg 90(3):717–721. doi: 10.1097/00000539-200003000-00038

Uesugi T, Mikawa K, Nishina K, Morikawa O, Takao Y, Obara H (2002) The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole. Anesth Analg 95(1):144–147

Memis D, Turan A, Karamanlioglu B, Saral P, Ture M, Pamukcu Z (2003) The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery. Anesth Analg 97(5):1360–1363

Goel C, Anand LK, Gombar K (2006) Comparative evaluation of single dose intravenous pantoprazole and ranitidine on gastric pH and volume: a double-blind study. J Anaesthesiol Clin Pharmacol 22(2):145–9